Free Access
Issue
J Extra Corpor Technol
Volume 52, Number 3, September 2020
Page(s) 212 - 217
DOI https://doi.org/10.1051/ject/202052212
Published online 15 September 2020
  1. Sniecinski RM, Levy JH Anticoagulation management associated with extracorporeal circulation. Best Pract Res Clin Anaesthesiol. 2015;29:189–202. [CrossRef] [PubMed] [Google Scholar]
  2. Lander H, Zammert M, FitzGerald D Anticoagulation management during cross-clamping and bypass. Best Pract Res Clin Anaesthesiol. 2016;30:359–70. [CrossRef] [PubMed] [Google Scholar]
  3. Hattersley PG Progress report: The activated coagulation time of whole blood (ACT). Am J Clin Pathol. 1976;66:899–904. [CrossRef] [PubMed] [Google Scholar]
  4. Bull BS, Korpman RA, Huse WM, et al. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975;69:674–84. [CrossRef] [PubMed] [Google Scholar]
  5. Ojito JW, Hannan RL, Burgos MM, et al. Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution. J Extra Corpor Technol. 2012;44:15–20. [PubMed] [Google Scholar]
  6. Svenmarker S, Appelblad M, Jansson E, et al. Measurement of the activated clotting time during cardiopulmonary bypass: Differences between hemotec ACT and Hemochron Jr apparatus. Perfusion. 2004;19:289–94. [CrossRef] [PubMed] [Google Scholar]
  7. Searles B Urban myths and the ACT: What is not true and what really matters when it comes to monitoring anticoagulation. J Extra Corpor Technol. 2006;38:56–8. [PubMed] [Google Scholar]
  8. Culliford AT, Gitel SN, Starr N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg. 1981;193:105–11. [CrossRef] [PubMed] [Google Scholar]
  9. Bosch YP, Ganushchak YM, de Jong DS Comparison of ACT point-of-care measurements: Repeatability and agreement. Perfusion. 2006;21:27–31. [CrossRef] [PubMed] [Google Scholar]
  10. ISO/IEC. Conformity Assessment—General Requirements for Accreditation Bodies Accrediting Conformity Assessment Bodies. Geneva, Switzerland: Geneva, International Organization for Standardization; 2004 [cited 2020 January 9]. [Google Scholar]
  11. Hug MI, Di Bernardo S, Berger F, et al. Measurement of activated clotting time in children--comparison of the Celite i-STAT ACT with the Medtronic ACT II. Acta Anaesthesiol Scand. 2004;48:211–7. [CrossRef] [PubMed] [Google Scholar]
  12. Lewandrowski EL, Van Cott EM, Gregory K, et al. Clinical evaluation of the i-STAT kaolin activated clotting time (ACT) test in different clinical settings in a large academic urban medical center: Comparison with the Medtronic ACT Plus. Am J Clin Pathol. 2011;135:741–8. [CrossRef] [PubMed] [Google Scholar]
  13. Davidsson FO, Johagen D, Appelblad M, et al. Reversal of heparin after cardiac surgery: Protamine titration using a statistical model. J Cardiothorac Vasc Anesth. 2015;29:710–4. [CrossRef] [PubMed] [Google Scholar]
  14. Medtronic Inc. Medtronic HMS Plus Hemostatis Management System Brochure: Medtronc Inc. 2020 Available at: http://www.medtronic.com/ihm/downloads/HMS_Plus_Brochure_200501780d_EN_FINAL.pdf. [Google Scholar]
  15. Abbot. The i-STAT Family of Products. 2020 Available at: https://www.pointofcare.abbott/int/en/offerings/istat. [Google Scholar]
  16. Bland JM, Altman DG Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–10. [CrossRef] [Google Scholar]
  17. Guzzetta NA, Monitz HG, Fernandez JD, et al. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. Anesth Analg. 2010;111:173–9. [CrossRef] [PubMed] [Google Scholar]
  18. Haselbach S, Maurer J, Vogel V, et al. A novel method for the direct determination of heparin concentration during cardiopulmonary bypass surgery. Clin Chem Lab Med. 2013;51:2037–43. [CrossRef] [PubMed] [Google Scholar]
  19. Ichikawa J, Hagihira S, Mori T, et al. In vitro and in vivo effects of hemodilution on kaolin-based activated clotting time predicted heparin requirement using a heparin dose-response technique. J Anesth. 2016;30:923–8. [CrossRef] [PubMed] [Google Scholar]
  20. Darlington DN, Delgado AV, Kheirabadi BS, et al. Effect of hemodilution on coagulation and recombinant factor VIIa efficacy in human blood in vitro. J Trauma. 2011;71:1152–63. [PubMed] [Google Scholar]
  21. Freedman MD Pharmacodynamics, clinical indications, and adverse effects of heparin. J Clin Pharmacol. 1992;32:584–96. [CrossRef] [PubMed] [Google Scholar]
  22. Schussler JM, Aguanno JJ, Glover EN, et al. Comparison of the i-STAT handheld activated clotting time with the Hemochron activated clotting time during and after percutaneous coronary intervention. Am J Cardiol. 2003;91:464–6. [CrossRef] [PubMed] [Google Scholar]
  23. Maslow A, Chambers A, Cheves T, et al. Assessment of heparin anticoagulation measured using i-STAT and Hemochron activated clotting time. J Cardiothorac Vasc Anesth. 2018;32:1603–8. [CrossRef] [PubMed] [Google Scholar]
  24. Despotis GJ, Joist JH, Hogue CWJr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46–54. [CrossRef] [PubMed] [Google Scholar]
  25. Hayashi Y, Brun MA, Machida K, et al. Simultaneous assessment of blood coagulation and hematocrit levels in dielectric blood coagulometry. Biorheology. 2017;54:25–35. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.